Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 1559 results for do not do recommendations

  1. Shared decision making in remote discussions: How do shared decision-making skills and techniques need to be modified for remote discussions?

    Recommendation ID NG197/5 Question Shared decision making in remote discussions: How do shared decision-making skills and...

    Research recommendation
    Published
    10 August 2021

  2. What key factors ensure people continue to walk or cycle in the long term (over a year)? How do individual interventions (such as follow-up or goal-setting) interact with environmental factors (such as distance, perception of danger or provision of facilities) in encouraging people to continue to walk or cycle?

    Recommendation ID PH41/4 Question What key factors ensure people continue to walk or cycle in the long term (over a year)? How...

    Research recommendation
    Published
    9 June 2015

  3. Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease (HTG689)

    Evidence-based recommendations on aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease in adults. This involves replacing the diseased part of the valve with some of the person’s own pericardium.

    HealthTech guidance
    Published
    9 August 2023
    View recommendations

    Sections for HTG689

  4. Caval valve implantation for tricuspid regurgitation (HTG726)

    Evidence-based recommendations on caval valve implantation for tricuspid regurgitation in adults. This involves implanting valves into 1 or both caval veins without disturbing the tricuspid valve.

    HealthTech guidance
    Published
    21 August 2024
    View recommendations

    Sections for HTG726

  5. E-cigarettes and established future smoking: Is e‑cigarette use in children, young people and young adults who do not smoke associated with future established smoking?

    Recommendation ID NG209/09 Question E-cigarettes and established future smoking: Is e‑cigarette use in children, young people and young

    Research recommendation
    Published
    17 December 2021

  6. Differing intervention effects in different groups: How do the same shared decision-making interventions differ in effectiveness between different groups of people and different care settings?

    Recommendation ID NG197/1 Question Differing intervention effects in different groups: How do the same shared...

    Research recommendation
    Published
    10 August 2021

  7. E-cigarette flavours: Do the flavours used in nicotine-containing e‑cigarettes have an impact on their effectiveness as an aid to stopping smoking, and are there any adverse effects associated with them?

    Recommendation ID NG209/08 Question E-cigarette flavours: Do the flavours used in nicotine-containing e‑cigarettes have an...

    Research recommendation
    Published
    17 December 2021

  8. Symptoms and signs of recurrent UTI:  Do the symptoms and signs of UTI in babies, children and young people aged under 16 years differ in those with a history of recurrent UTIs compared with those without a history of recurrent UTI?

    Recommendation ID NG224/03 Question Symptoms and signs of recurrent UTI: Do the symptoms and signs of UTI in babies,...

    Research recommendation
    Published
    4 August 2022

  9. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    14 February 2023
    View quality statements

    Sections for QS22

  10. Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

    Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA833

  11. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)

    Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.

    Technology appraisal guidance
    Published
    28 January 2026
    View recommendations

    Sections for TA1126

  12. Characteristics of a person delivering an intervention:- How do the professional characteristics of pharmacy staff affect the effectiveness and cost effectiveness of delivering information, advice, education or behavioural support to underserved groups and the general population? (Characteristics include, for example, job roles such as health champion, as well as competencies and level of training.)

    Recommendation ID NG102/4 Question Characteristics of a person delivering an intervention:- How do the professional...

    Research recommendation
    Published
    12 December 2018

  13. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab (TA612)

    Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.

    Technology appraisal guidance
    Published
    20 November 2019
    View recommendations

    Sections for TA612

  14. Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

    Evidence-based recommendations on icosapent ethyl (Vazkepa) with statin therapy for reducing the risk of cardiovascular events in adults with raised triglycerides.

    Technology appraisal guidance
    Published
    13 July 2022
    View recommendations

    Sections for TA805

  15. What are the most effective and cost-effective population-level measures to help people in mid-life maintain or adopt healthy behaviours and build up resilience to dementia, disability and frailty? What are the best methods for evaluating their effect? How do these measures affect health inequalities?

    Recommendation ID NG16/2 Question What are the most effective and cost-effective population-level measures to help people in mid-life...

    Research recommendation
    Published
    9 December 2015